help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stonesifer, L. D.
Right arrow Articles by Kohler, P. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stonesifer, L. D.
Right arrow Articles by Kohler, P. O.

Journal of Clinical Endocrinology & Metabolism, Vol 53, 931-934, Copyright © 1981 by Endocrine Society

ARTICLES

Somatomedin C in treated acromegaly: poor correlation with growth hormone and clinical response

LD Stonesifer, RM Jordan and PO Kohler

To determine the usefulness of commercially available somatomedin C levels in the evaluation of the treatment of acromegaly, 15 patients were tested at 0.25-15.4 yr after onset of therapy. Clinical response, as determined by a numerical scoring system, was compared with RIA of GH and somatomedin C. Symptomatic response was poorly correlated with somatomedin C (r = 0.033) as well as with GH (r = 0.24). The correlation of GH and somatomedin C was also poor (r = 0.46, P greater than 0.05). Eighty-three percent of patients with clinical improvement had GH less than or equal to 10 ng/ml, 50% had GH less than or equal to 5 ng/ml, while 42% had somatomedin C less than or equal to 3.0 U/ml. All patients who were evaluated at 1 yr or less after therapy had elevated somatomedin C levels with normal or near normal GH values. In contrast only 2 of 11 patients evaluated at more than 1 yr after therapy had a mild persistence of somatomedin C elevation with normal GH levels. Determination of somatomedin c costs more than GH determinations and appears to offer no apparent advantage over GH in following patients treated for acromegaly.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
J. J. Puder, S. Nilavar, K. D. Post, and P. U. Freda
Relationship between Disease-Related Morbidity and Biochemical Markers of Activity in Patients with Acromegaly
J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 1972 - 1978.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
G. A. Kaltsas, A. M. Isidori, D. Florakis, P. J. Trainer, C. Camacho-Hubner, F. Afshar, I. Sabin, J. P. Jenkins, S. L. Chew, J. P. Monson, et al.
Predictors of the Outcome of Surgical Treatment in Acromegaly and the Value of the Mean Growth Hormone Day Curve in Assessing Postoperative Disease Activity
J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1645 - 1652.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1981 by The Endocrine Society